Autologous Stem Cell and Non-Stem Cell-based Therapies Global Market Report 2024

The autologous stem cell and non-stem cell based therapies market size has grown rapidly in recent years. It will grow from $8.58 billion in 2023 to $9.96 billion in 2024 at a compound annual growth rate (CAGR) of 16.1%. The growth observed during the historical period can be attributed to several factors, including the increased prevalence of cancer and diabetes, a rise in the number of geriatric individuals, growing healthcare awareness, an increase in research and development activities, a higher number of clinical trials, and increased regulatory approvals.

The autologous stem cell and non-stem cell based therapies market size is expected to see rapid growth in the next few years. It will grow to $18.16 billion in 2028 at a compound annual growth rate (CAGR) of 16.2%. The anticipated growth in the forecast period can be attributed to several factors, including the rising prevalence of targeted diseases, an increasing geriatric population, a growing incidence of neurodegenerative diseases, the rise in cancer cases, an increasing demand for skin transplantation, and a growing awareness about regenerative medicine. Additionally, collaborations and partnerships among key players and improving reimbursement for approved therapies are contributing factors. Major trends expected in the forecast period include the integration of artificial intelligence and machine learning, the development of off-the-shelf allogeneic stem cell products, the expansion of reimbursement policies, the adoption of novel biomaterials, advancements in cell manufacturing technologies, the adoption of autologous stem cell therapies, and the integration of gene editing technologies.

The increasing demand for personalized therapies is set to drive the growth of the autologous stem cell and non-stem cell-based therapies market in the foreseeable future. Personalized therapies refer to medical treatments tailored to maximize benefits and minimize adverse effects based on individual genetics, lifestyle, and preferences. This surge in personalized therapies can be attributed to several factors, including advancements in genetics and technology enabling more precise and effective treatments with reduced side effects, growing patient preference for customized care, and the potential for cost savings in healthcare. Personalized therapies optimize the utilization of autologous stem cell and non-stem cell-based treatments by tailoring them to the unique genetic and health characteristics of each individual, resulting in improved outcomes and fewer complications. For example, data from the Personalized Medicine Coalition in 2022 indicated that the approval of 12 new personalized medicines accounted for around 34% of all newly approved therapies, signaling a significant increase from previous years. Hence, the increasing demand for personalized therapies serves as a driving force for the autologous stem cell and non-stem cell-based therapies market.

Prominent companies in the autologous stem cell and non-stem cell-based therapies market are focusing on the development of tumor-derived autologous T cell immunotherapy to enhance personalized cancer treatment strategies. Tumor-derived autologous T cell immunotherapy involves extracting T cells from a patient's tumor, expanding and activating them in the laboratory, and reintroducing them into the patient to boost the immune system's ability to target and eradicate cancer cells specifically. For instance, in February 2024, Iovance Biotherapeutics, a US-based biotechnology company, obtained accelerated approval from the Food and Drug Administration for Amtagvi (lifileucel), the first cellular therapy indicated for treating adult patients with melanoma. Lifileucel, a tumor-derived autologous T-cell immunotherapy, consists of a patient's naturally occurring immune cells known as tumor-infiltrating lymphocytes (TILs), enhancing the immune system's ability to recognize and combat cancer more effectively.

In April 2022, Metcela Inc., a Japan-based biotechnology company, acquired Japan Regenerative Medicine Co. Ltd. (JRM) for an undisclosed sum. Through this acquisition, Metcela Inc. aims to expand its portfolio with an autologous cell product for pediatric congenital heart disease and leverage synergies in manufacturing and sales systems for a wide range of cardiac therapies. Japan Regenerative Medicine Co. Ltd. (JRM) specializes in developing regenerative medicine therapies for pediatric congenital heart diseases and offers services related to stem cell therapy.

Major companies operating in the autologous stem cell and non-stem cell based therapies market are Bayer AG, Novartis AG, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Merck & Co. Inc., Stemcell Technologies Inc., Dendreon Corporation, Vericel Corporation, Sangamo Therapeutics Inc., NEOSTEM, Orgenesis Inc., Adaptimmune Therapeutics, Stempeutics Research Pvt Ltd., MEDIPOST, Castle Creek Biosciences Inc., BrainStorm Cell Limited, Athersys Inc., Cytori Therapeutics Inc., Opexa Therapeutics, Gamida Cell, Regen BioPharma Inc., RepliCel Life Sciences, InGeneron Inc., BioCardia Inc., ReNeuron Group.

North America was the largest region in the autologous stem cell and non-stem cell based therapies market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the autologous stem cell and non-stem cell based therapies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the autologous stem cell and non-stem cell based therapies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Autologous stem cell and non-stem cell-based therapies encompass treatments that utilize a patient's own cells to repair, replace, or regenerate damaged tissues and organs. In autologous stem cell therapies, stem cells are extracted from the patient, expanded or modified, and reintroduced to facilitate healing and regeneration. Non-stem cell-based therapies, on the other hand, utilize different types of cells, such as immune cells or tissue-specific cells, to achieve similar therapeutic objectives. These personalized approaches aim to mitigate the risk of immune rejection and enhance treatment efficacy for conditions such as cancer, autoimmune diseases, and degenerative disorders.

The primary types of autologous stem cell and non-stem cell-based therapies include autologous stem cells, autologous non-stem cells, and others. Autologous stem cells are derived from the patient's own body and utilized in medical therapies to facilitate the healing of damaged tissue or organs. They find application across various fields including cancer treatment, neurodegenerative disorders, cardiovascular disease, orthopedic conditions, and others, and are utilized by hospitals, ambulatory surgical centers, research facilities, and other healthcare institutions.

The autologous stem cell and non-stem cell based therapies market research report is one of a series of new reports that provides autologous stem cell and non-stem cell based therapies market statistics, including the autologous stem cell and non-stem cell based therapies industry global market size, regional shares, competitors with autologous stem cell and non-stem cell based therapies market share, detailed autologous stem cell and non-stem cell based therapies market segments, market trends, and opportunities, and any further data you may need to thrive in the autologous stem cell and non-stem cell based therapies industry. These autologous stem cell and non-stem cell based therapies market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The autologous stem cell and non-stem cell-based therapies market consists of revenues earned by entities by providing services such as patient evaluation, cell collection and processing, genetic modification, quality control, cell storage, infusion, post-treatment monitoring, regulatory compliance, and patient support services. The market value includes the value of related goods sold by the service provider or included within the service offering. The autologous stem cell and non-stem cell-based therapies market also includes sales of platelet-rich plasma (PRP) therapy, autologous fibroblast injection, autologous dendritic cell therapy, and tumor-derived autologous T cell immunotherapy. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.